Bolt Biotherapeutics appoints Laura Berner to Board of Directors

Bolt Biotherapeutics, Inc.

Board expanded from 9 to 10; Laura Berner appointed as Class I director, term through 2025 annual meeting.
Berner qualifies as independent under Nasdaq rules; no reportable related-party transactions.
Received initial option award for 50,000 shares, vesting over 36 months, and prorated option for 12,261 shares.
Eligible for annual option of 25,000 shares and $35,000 cash retainer under non-employee director compensation policy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Laura Berner

Class I Director

BOLT · Bolt Biotherapeutics, Inc.

Effective: 2022-12-14
Filed: December 14, 2022, 6:59 PM ET

the Board then appointed Laura Berner to the Board as a Class I director of the Company, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Laura Berner was appointed as Class I Director at Bolt Biotherapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

the Board then appointed Laura Berner to the Board as a Class I director of the Company, effective immediately

View on SEC.gov

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-026551

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.